Chengdu Fannuoxi Biomedical Technology

Chengdu Fannuoxi Biomedical Technology is a clinical-stage biopharmaceutical company specializing in the discovery and development of innovative small molecule drugs for metabolic and inflammatory diseases. The company utilizes a proprietary structure-based drug design (SBDD) platform to develop highly potent and selective candidates, with a particular focus on the incretin space. Its pipeline features several promising candidates, including a URAT1 inhibitor for gout currently in Phase 2 clinical trials. Fannuoxi is also advancing multi-target agonists, such as GLP-1R/GIPR/GCGR triple agonists, aimed at treating obesity and type 2 diabetes. The company's primary goal is to provide effective oral alternatives to traditional injectable therapies, improving patient convenience and adherence. Based in the Chengdu High-tech Zone, Fannuoxi has attracted significant investment from regional venture capital firms to support its R&D efforts.